2009, Number 3
<< Back Next >>
Rev Med MD 2009; 1 (3)
Levosimendán: un abordaje prometedor en el manejo de la Insuficiencia Cardiaca
Castañeda-Castañeda DF, Ramírez-Grajeda IN
Language: Spanish
References: 36
Page:
PDF size: 319.48 Kb.
ABSTRACT
No Abstrac
REFERENCES
1.Carrillo-Esper Raúl, Sánchez-Zúñiga Martín, Actualidades en inotrópicos, Revista Mexicana de Anestesiología, Octubre-Diciembre 2005, Vol. 28. No. 4, 208-216.
2.Feldman David, MD, PhD, Menachemi Doron M., et al., Management Strategies for Stage-D Patients with Acute Heart Failure, Clin Cardiol, 2008 July. Vol. 31 No.7 pp 297–301.
3.González-Chon Octavio, García López Sandra María del Carmen, et al., Levosimendan: Nueva estrategia en el manejo de la falla cardíaca, Archivos de Cardiologia de Mexico, 2005, Vol. 75: S3, 130-139.
4.Erhardt Leif R.., Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?, Ital Heart J, 2003, Vol 4 Suppl, pp 27S-33S.
5.Nieminen Markku S., MD, PhD, Pollesello Piero, PhD,† et al., Effects of Levosimendan on the Energy Balance:Preclinical and Clinical Evidence, J Cardiovasc Pharmacol, 2009, Vol. 53, pp302–310.
6.Archan Sylvia and Toller Wolfgang, Levosimendan: current status and future prospects, Current Opinion in Anaesthesiology, 2008, Vol. 21, pp78–84.
7.M Endoh, Could Ca2+ sensitizers rescue patients from chronic congestive heart failure?, British Journal of Pharmacology, 2007, Vol. 150, pp826–828.
8.Toller Wolfgang G., M.D., Stranz Christian, M.D, Levosimendan, a New Inotropic and Vasodilator Agent, Anesthesiology, March 2006, Vol. 104, No 3, 556-569.
9.Parissis John T., Rafonil- Stergiou, et al., Levosimendan: from basic science to clinical practice, Heart Fail Rev, 2008, DOI 10.1007/s10741-008-9128-4.
Del-Razo Oscar E., Carballal Sanjurjo Julio C., et al., Levosimendan: Una nueva opción en el manejo farmacológico de la insuficiencia cardíaca, Gac Méd Méx, 2003, Vol. 139 No. 1, pp. 87-89.
11.Delgado Juan F, Levosimendán en la insuficiencia cardiaca aguda: pasado, presente y futuro, Rev Esp Cardiol, 2006, Vol. 59, No.4, pp309-12.
12.Papp Zoltán, Csapó Kálmán, et al., Pharmacological Mechanisms Contributing to the Clinical Efficacy of Levosimendan. Cardiovascular Drug Reviews, 2005, Vol. 23, No. 1, pp. 71–98.
13.Carretero-Colomer Marián, Levosimendán Mejora del estado hemodinámico de los pacientes con insuficiencia cardíaca descompensada, Actualidad científica Medicamentos de vanguardia, Septiembre 2006. Vol. 25, No.8, pp 120-12.
14.Weis Florian, MD, Beiras-Fernandez Andres, MD, Kaczmarek Ingo, MD,Sodian Ralf, MD, PhD, Kur Felix, MD, Weis Marion, MD, et al., Levosimendan: A New Therapeutic Option in the Treatment of Primary Graft Dysfunction After Heart Transplantation, J.healun, 2009, 01.017.
15.Banfor Patricia N., Preusser Lee C., Campbell Thomas J., Marsh Kennan C., Polakowski James S., Reinhart Glenn A., et al., Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs, Am J Physiol Heart Circ Physiol, January 2008, Vol 294: H238–H248.
16.Birhan-Yilmaz Mehmet, Kenan Yalta, Yontar Can, Karadas Filiz, Erdem Alim, Onur-Turgut Okan, et al., Levosimendan Improves Renal Function in Patients with Acute Decompensated Heart Failure: Comparison with Dobutamine, Cardiovasc Drugs Ther, 2007, Vol. 21, pp431–435.
17.Michaels Andrew D., MD; McKeown Barry, MD; Kostal Michael, MD; Vakharia Kalpesh T., BA, BSE; Jordan Mark V., MD; Gerber Ivor L., MD, et al., Effects of Intravenous Levosimendan on Human Coronary Vasomotor Regulation, Left Ventricular Wall Stress, and Myocardial Oxygen Uptak, Circulation, Journal of the American Heart Association. January 2005. Vol. 111, 1504-1509.
18.Braunwald Eugene, Capítulo 217: Basic biology of the cardiovascular system, Publicado en Harrison’s principles of Internal Medicine, 17º edición, United States of America, McGraw-Hill, 2008.
19.Goldman Lee, MD, Ausiello Dennis, MD, Capítulo 50: Cardiac function and Circulatory control, Publicado en Cecil Medicine, 13º edición, United States of America, Saunders Elsevier, 2007.
20.H. Opie Lionel, Microanatomy of contractile cells and Proteins, Publicado en Braunwald: Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed, United States of America, Saunders Company, 2001.
21.Robertson Ian M., Baryshnikova Olga K., et al., Defining the Binding Site of Levosimendan and Its Analogues in a Regulatory Cardiac Troponin C-Troponin I Complex. Biochemistry, 2008, Vol. 47, pp 7485–7495.
22.Kyrzopoulos Stamos, Adamopoulos Stamatis, Parissis John T., Rassias John, Kostakis George, Iliodromitis Efstathios, et al., Levosimendan reduces plasma Btype natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients, International Journal of Cardiology, 2005, Vol. 99, pp 409– 413.
23.Givertz Michael M., Costa Andreou, et al., Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction Alteration of Force-Frequency and Relaxation-Frequency Relationships. Circulation, Journal of the American Heart Association, 2007, Vol. 115, pp1218-1224.
24.Bowman Peggy, Haikala Heimo and Paul Richard J., Levosimendan, a Calcium Sensitizer in Cardiac Muscle,Induces Relaxation in Coronary Smooth Muscle Through Calcium Desensitization, JPET, 1999, Vol. 288, No. 1, pp :316–325.
25.Magliola Ricardo, Moreno Guillermo, Vassallo Juan C., Landry Luis M., Althabe María, Balestrini María, et al., Levosimendán, un nuevo agente inotrópico: experiencia en niños con fallo cardíaco agudo, Arch Argent Pediatr, 2009, Vol. 107, No.2. pp139-145.
26.Du Toit EF, A Genis, et al., A role for the RISK pathway and KATP channels in pre-and post-conditioning induced by Levosimendan in the isolated guinea pig heart, British Journal of Pharmacology, 2008, Vol. 154, pp41–50.
27.V. S. Moiseyev, P. Po˜ der, N. Andrejevs, M. Y. Ruda, A. P. Golikov, L. B. Lazebnik, et al., Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction A randomized, placebo-controlled, doubleblind study (RUSSLAN). European Heart Journal, 2002, Vol. 23, pp1422–1432.
28.Álvarez Julián, Levosimendan and Low Cardiac Output Syndrome. Does Mortality Really Decrease?, Rev Esp Cardiol, 2008, Vol. 61, No.5, pp454-457.
29.Mebazaa Alexandre; Nieminen Markku S., et al., Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure The SURVIVE Randomized Trial. JAMA, 2007, Vol. 297, No.17, pp1883-1891.
30.Yakut Necmettin, Yasa Haydar, Bahrıye Lafcı Banu, Ortac Ragıp, Tulukoglu Engin, Aksun Murat, et al., The influence of levosimendan and iloprost on renal ischemia– reperfusion: an experimental study, Interact CardioVasc Thorac Surg, 2008, Vol. 7, pp235-239.
31.Varpula Tero, MD, PhD, Rapola Janne, MD, PhD et al., Treatment of Serious Calcium Channel Blocker Overdose With Levosimendan, a Calcium Sensitizer. International Anesthesia Research Society, Anesth Analg, March 2009. Vol. 108, No. 3, 108:790–792.
32.De Hert Stefan G., MD, PhD, Lorsomradee Suraphong, MD, et al. A Randomized Trial Evaluating Different Modalities of Levosimendan Administration in Cardiac Surgery Patients With Myocardial Dysfunction, Journal of Cardiothoracic and Vascular Anesthesia, October 2008. Vol. 22, No 5 pp 699-705.
33.Yildiz Oguzhan, Vasodilating Mechanisms of Levosimendan: Involvement of K+ Channels, Journal of Pharmacological Sciences, 2007, Vol.104,pp 1-5.
34.Kass David A., MD; Solaro R. John, PhD, Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart. Circulation Journal of the American Heart Association, 2006, Vol. 113 pp305-315.
35.Lehtonen Lasse, MD, PhD, Levosimendan: A Calcium-sensitizing Agent for the Treatment of Patients with Decompensated Heart Failure, Current Heart Failure Reports, 2004, Vol. 1, pp136–144.
36.Lasse Lehtonen, MD, PhD, Levosimendan: A Promising Agent for the Treatment of Hospitalized Patients with Decompensated Heart Failure, Current Cardiology Reports, 2000, Vol. 2, pp233-243
Full text